These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28646725)

  • 21. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
    Harder MJ; Höchsmann B; Dopler A; Anliker M; Weinstock C; Skerra A; Simmet T; Schrezenmeier H; Schmidt CQ
    Front Immunol; 2019; 10():1639. PubMed ID: 31379839
    [No Abstract]   [Full Text] [Related]  

  • 22. Eculizumab effect on the hemostatic state in patients with paroxysmal nocturnal hemoglobinuria.
    Seregina EA; Tsvetaeva NV; Nikulina OF; Zapariy AP; Erasov AV; Gribkova IV; Orel EB; Ataullakhanov FI; Balandina AN
    Blood Cells Mol Dis; 2015 Feb; 54(2):144-50. PubMed ID: 25497169
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria.
    Reiss UM; Schwartz J; Sakamoto KM; Puthenveetil G; Ogawa M; Bedrosian CL; Ware RE
    Pediatr Blood Cancer; 2014 Sep; 61(9):1544-50. PubMed ID: 24777716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful management of obstructive jaundice due to gallstones with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria.
    Kawano H; Minagawa K; Wakahashi K; Kawano Y; Sada A; Matsui T; Hirano H; Shiomi H; Ku Y; Katayama Y
    Intern Med; 2012; 51(18):2613-6. PubMed ID: 22989836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria.
    Zareba KM
    Drugs Today (Barc); 2007 Aug; 43(8):539-46. PubMed ID: 17925885
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
    N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of complement inhibition in PNH.
    Hillmen P
    Hematology Am Soc Hematol Educ Program; 2008; ():116-23. PubMed ID: 19074068
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria.
    Gurnari C; Graham AC; Efanov A; Pagliuca S; Durrani J; Awada H; Patel BJ; Lichtin AE; Visconte V; Sekeres MA; Maciejewski JP
    Blood Cells Mol Dis; 2021 Mar; 87():102528. PubMed ID: 33341510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial.
    Kanakura Y; Ohyashiki K; Shichishima T; Okamoto S; Ando K; Ninomiya H; Kawaguchi T; Nakao S; Nakakuma H; Nishimura J; Kinoshita T; Bedrosian CL; Ozawa K; Omine M
    Int J Hematol; 2013 Oct; 98(4):406-16. PubMed ID: 23934275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria.
    McKeage K
    Drugs; 2011 Dec; 71(17):2327-45. PubMed ID: 22085388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Successful eculizumab treatment for multiple coronary thrombosis complicated in paroxysmal nocturnal hemoglobinuria].
    Taniguchi A; Ikezoe T; Takeuchi A; Togitani K; Yoshimoto M; Tanioka K; Kitaoka H; Yokoyama A
    Rinsho Ketsueki; 2014 Aug; 55(8):965-9. PubMed ID: 25186487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of pregnancy in paroxysmal nocturnal hemoglobinuria on long-term eculizumab.
    Vekemans MC; Lambert C; Ferrant A; Saussoy P; Havelange V; Debiève F; Van Den Neste E; Michaux L
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):464-6. PubMed ID: 25688464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule.
    Gatault P; Brachet G; Ternant D; Degenne D; Récipon G; Barbet C; Gyan E; Gouilleux-Gruart V; Bordes C; Farrell A; Halimi JM; Watier H
    MAbs; 2015; 7(6):1205-11. PubMed ID: 26337866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Results of phase Ib open multicenter clinical trial of the safety, pharmacokinetics and pharmacodynamics of first biosimilar of eculizumab in untreated patients with paroxysmal nocturnal hemoglobinuria during induction of therapy].
    Ptushkin VV; Kulagin AD; Lukina EA; Davydkin IL; Konstantinova TS; Shamrai VS; Minaeva NV; Kudlay DA; Gapchenko EV; Markova OA; Borozinets AY
    Ter Arkh; 2020 Sep; 92(7):77-84. PubMed ID: 33346448
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: Real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry.
    Höchsmann B; de Fontbrune FS; Lee JW; Kulagin AD; Hillmen P; Wilson A; Marantz JL; Schrezenmeier H
    Eur J Haematol; 2022 Sep; 109(3):197-204. PubMed ID: 35390189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population.
    Cheng WY; Sarda SP; Mody-Patel N; Krishnan S; Yenikomshian M; Mahendran M; Lejeune D; Yu LH; Duh MS
    Adv Ther; 2021 Aug; 38(8):4461-4479. PubMed ID: 34275086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab.
    Röth A; Dührsen U
    Eur J Haematol; 2011 Dec; 87(6):473-9. PubMed ID: 21883481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
    Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical progress of paroxysmal nocturnal hemoglobinuria].
    Gong YW; He GS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1627-30. PubMed ID: 24370061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persisting hyperbilirubinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with eculizumab: The role of hepatocanalicular transporter variants.
    Alashkar F; Weber SN; Vance C; Herich-Terhürne D; Dührsen U; Lammert F; Röth A
    Eur J Haematol; 2017 Oct; 99(4):350-356. PubMed ID: 28692147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.